Amoeba

The company’s capital structure is highly leveraged, with total liabilities of €15.5 billion and total equity of -€5.4 billion, resulting in a debt-to-equity ratio of -2.28. Liquidity is constrained, as evidenced by a current ratio of 0.98 and negative free cash flow of -€8.4 million. The negative net income of -€8.3 million and operating income of -€67.8 million indicate a severe earnings shortfall, with return on assets at -8.2% and return on equity at 154.86% due to negative equity.

Profitability metrics are sharply below industry norms for agricultural chemicals, where positive operating margins and stable ROIC are typically expected. The company’s negative gross profit of -€631.3 million and operating cash flow of -€6.1 million suggest operational inefficiencies and declining pricing power.

Geographic and segment exposure is not disclosed in the available data, but the company’s negative equity and high debt load imply a concentration risk in its core operations. The absence of revenue by segment or region limits visibility into diversification or exposure to volatile markets.

Growth is not evident in the current financials, with no revenue reported and a negative operating cash flow. Analysts have assigned a mean price target of €1.47, but the median recommendation of 1.67 (closer to "hold") reflects uncertainty about the company’s ability to reverse its losses.

The risk profile is elevated, with liquidity risk rated as medium and a negative net cash position. The company’s dilution risk is low, but the absence of positive equity and high leverage increase the likelihood of financial distress.

Recent filings and transcripts are not available in the provided data, but the financial snapshot indicates a deteriorating position in the most recent reporting period. Analysts have not issued strong buy recommendations, and the price target range of €1.10 to €1.90 suggests limited upside.